BioNTech SE

BNTXintermediary

BioNTech is a German biotechnology company that co-developed the first authorized mRNA COVID-19 vaccine with Pfizer. It is now leveraging its mRNA platform for individualized cancer vaccines, infectious disease programs, and cell therapies.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($4.8B)

Static data (loading live financials…)

COVID-19 Vaccine Revenue (68%)

Collaboration Revenue (Pfizer) (18%)

R&D Grants & Other (14%)

Segment Breakdown & Key Customers

Product Details

Comirnaty (COVID-19 Vaccine)55%

mRNA-based COVID-19 vaccine developed with Pfizer

Oncology mRNA (BNT111, BNT122)15%

Individualized mRNA cancer vaccines targeting solid tumors

Infectious Disease Pipeline10%

mRNA vaccines for influenza, shingles, and malaria

Supply Chain Relationships

Partners

Pfizer Inc.

Comirnaty COVID vaccine co-development

Impact: Critical — Pfizer is primary commercialization partner

Competitors

Moderna, Inc.

mRNA vaccines and oncology

Impact: Primary mRNA competitor

Regeneron Pharmaceuticals

Cancer immunotherapy

Impact: Competing in oncology

Macro & Market Context

제약 / 바이오Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Upcoming Catalysts

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of BioNTech SE.

Company Info

Headquarters

Mainz, Germany

Founded

2008

Employees

6,000+

Website

biontech.com

Sector Overview — 제약 / 바이오

Sector News